News | August 13, 2008

Study Says Usage of Ultrasound Contrast Agents in Echocardiography Declined

August 14, 2008 - Arlington Medical Resources (AMR), a provider of market intelligence for the pharmaceutical and diagnostic imaging industries, found the usage of injectable perflutren microsphere ultrasound (micro-bubble) contrast agents, which help to evaluate heart wall motion, declined in the second quarter of 2008 to 22 percent of the usage just two years earlier.

Micro-bubble contrast agents are gas-filled microspheres injected intravenously to improve cardiac ultrasound scanning. In October 2007 the FDA placed a black box warning on ultrasound micro-bubble contrast agents after 10 deaths were reported following administration. Reports of 190 serious but nonfatal reactions were also documented.

“The effects of the black box warnings in 2007 are still being felt in the micro-bubble contrast agent market,” said Anna Fisher, an analyst at AMR. “Even after the FDA revised its warning in May 2008 allowing the agents to be used more broadly, usage still declined in the second quarter of 2008. The role of ultrasound contrast agents continues to be important in the overall echocardiography market because it enhances imaging quality for interpretation. Contrast improves visualization of the left ventricle border, helping the physician evaluate wall motion of the heart.”

The newly released edition of the U.S. Echocardiography Monthly Monitor also finds that the total number of patients undergoing echocardiographies in the U.S. had declined by 17,095 in June 2008. The total number of patients undergoing contrast enhanced echocardiography for the U.S. market also declined slightly by 2,137.

For more information: www.AMR-data.com

Related Content

Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Launches Acuson Sequoia Ultrasound
Technology | Ultrasound Imaging | July 12, 2018
July 12, 2018 — Siemens Healthineers recently announced the launch of its new ultrasound system, the Acuson Sequoia.
EchoNous Vein Receives FDA Approval to Improve First-Time Peripheral IV Catheter Insertion
Technology | Ultrasound Imaging | July 12, 2018
EchoNous has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EchoNous Vein, an ultrasound-...
Zebra Medical Vision Announces FDA 510(k) Clearance of Coronary Calcium Algorithm
Technology | Computed Tomography (CT) | July 12, 2018
Zebra Medical Vision has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Coronary...
Hologic Announces Availability of Viera Portable Breast Ultrasound System
Technology | Ultrasound Women's Health | July 11, 2018
Hologic’s new Viera portable breast ultrasound system is now available for purchase in the United States and Europe....
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Healcerion Receives FDA Approval for Sonon 300L Handheld Ultrasound Device
Technology | Ultrasound Imaging | July 09, 2018
South Korea-based Healcerion launched the Sonon 300L wireless handheld ultrasound device to the U.S. market following U...
HeartFlow Announces New Commercial Coverage With UnitedHealthcare
News | Computed Tomography (CT) | July 03, 2018
HeartFlow Inc. announced that UnitedHealthcare now covers the HeartFlow FFRct Analysis, extending access to their 45...
Neural Analytics Inc. Receives CE Mark for Robotic Ultrasound System
Technology | Ultrasound Imaging | July 03, 2018
Medical robotics company Neural Analytics Inc. announced that it received CE Mark for its NeuralBot System, a robotic...
Overlay Init